Intervention

AZD9291

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 14 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials14

Recruiting0

Common conditions14

Lead sponsors shown6

Clinical trials

14 shown

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMSNCT03257124 · 2017-05-08

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNANCT02811354 · 2017-02-24

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLCNCT02771314 · 2016-08-02

Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain MetastasesNCT02736513 · 2016-05-01

Uncommon EGFR AZD9291NCT03424759 · 2016-01-01

AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational StudiesNCT02504346 · 2015-08-01

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive TumoursNCT02454933 · 2015-07-15

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia PacificNCT02442349 · 2015-06-22

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)NCT02157883 · 2014-11-06

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung CancerNCT02228369 · 2014-11-05

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung CancerNCT02179671 · 2014-07-25

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive TumoursNCT02094261 · 2014-05-20

AZD9291 First Time In Patients Ascending Dose StudyNCT01802632 · 2013-03-04

AZD9291 US Expanded Access ProgramNCT02451852

NO_LONGER_AVAILABLE

Common conditions

Non Small Cell Lung Cancer3 Advanced (Inoperable) Non Small Cell Lung Cancer2 Advanced Non Small Cell Lung Cancer2 Lung Cancer2 Carcinoma, Non-Small-Cell Lung1 EGFR Mutation Positive Advanced Non Small Cell Lung Cancer1 EGFR T790M Mutation Positive NSCLC1 Failed Tyrosine Kinase Inhibitors1 Locally Advanced or Metastatic EGFR T790M+ NSCLC1 Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)1 Non-Small Cell Lung Cancer1 Non-Small Cell Lung Cancer With EGFR T790M Mutation1 Targeted Therapy1 With Brain and/or Leptomeningeal Metastasis1

Leading sponsors

AstraZeneca 8 Samsung Medical Center 2 Hellenic Oncology Research Group 1 National University Hospital, Singapore 1 Oslo University Hospital 1 Soroka University Medical Center 1

Trial status mix

COMPLETED7

UNKNOWN6

NO_LONGER_AVAILABLE1

Phase mix

PHASE210

PHASE13

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.